Rathmann et al. performed the observational study, utilizing a database of ICD code filled in by primary care physicians, to analyze the association between DPP-4 inhibitor therapy and the risk of metastasis in T2DM patients with newly diagnosed breast, prostate and digestive organ cancers [131]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.